- NHS England and NHS Improvement sign two-year deal for QIAGEN’s HGMD bioinformatics
- HGMD (Human Gene Mutation Database) will be used at seven sites to aid interpretation of genomic data from next-generation sequencing (NGS)
- Deal highlights HGMD's lead role interpreting NGS results for inherited diseases
- NGS data from over 2.5 million clinical cases now analyzed and interpreted by QIAGEN Digital Insights solutions
Manchester, England, and Hilden, Germany, March 2, 2022 – QIAGEN today announced a new two-year licensing agreement with NHS England and NHS Improvement, one of the four public healthcare systems in the United Kingdom. NHS England and NHS Improvement will use QIAGEN’s HGMD Online Professional, the largest, human-certified curated resource for finding disease-causing genetic variants, to support scientists and clinician across its network of 7 NHS Laboratory Hubs (GLHs) in England with clinical reporting and interpretation of genomic data from patients affected by rare genetic disorders.
The agreement marks a significant milestone in QIAGEN’s longstanding collaboration with the NHS and builds on the selection of HGMD Professional by Genomics England to support the 100,000 Genomes Project. This now-completed UK Government initiative sequenced 100,000 complete genomes from individuals with hereditary cancer or rare diseases to improve the diagnosis and future care of genetic disorders. The continued use of HGMD also supports the NHS’s ongoing mission to expand the diversity and reach of genomics in the UK to enable faster, more comprehensive genomic testing on a national scale.
In the UK, more than half a million children and adults are currently affected by genetic diseases, with approximately 30,000 babies born each year with a genetic disorder.1 The new Genome UK strategy aims to analyze five million genomes in the UK by 2023/2024, including the sequencing of 500,000 whole genomes through the NHS Genomic Medicine Service.
“We are honored to provide this service to the NHS and to put the most detailed, up-to-date evidence-based genomic information into the hands of scientists and clinicians performing genetic testing,” said Jonathan Sheldon, Senior Vice President and Head of QIAGEN Digital Insights. “HGMD Professional offers users a digital encyclopedia of peer-reviewed genetic information, enabling confident diagnoses in a much more efficient and targeted manner. Our teams at QIAGEN Digital Insights are continuously striving to deliver valuable molecular insights and clinical bioinformatics solutions that will enable predictive, preventative, and personalized care with confidence, and that improve patient outcomes.”
Founded and maintained in 1996 by the Institute of Medical Genetics at Cardiff University, Wales, QIAGEN’s HGMD Professional attempts to collate all known (published) gene lesions responsible for human inherited disease, giving users the confidence that the catalogued mutation is properly reported and relevant.
Unlike new machine learning or artificial intelligence platforms that rapidly index millions of journal articles for mutations, HGMD Professional leverages human judgement and expertise – every catalogued genetic variant has been “touched” by a trained scientist to ensure accuracy, relevance, and context. To date, HGMD Professional contains over 352,000 detailed reports on individual gene variants, with over 45,000 new reports added in 2021 alone.
With more than three decades of experience in variant curation, QIAGEN understands the challenges labs face as next-generation sequencing (NGS) advances. The QIAGEN Clinical Insights (QCI) portfolio consists of QIAGEN’s clinical decision support software and molecular databases, including HGMD Professional, the Catalogue Of Somatic Mutations In Cancer (COSMIC), and the most recently added Human Somatic Mutation Database (HSMD).”
More information on HGMD Professional can be found here.
For an overview of QIAGEN’s molecular knowledge and bioinformatics solutions, please visit: https://digitalinsights.qiagen.com/
1 Genetic Alliance UK. (2021). Genetic disorders UK. https://geneticalliance.org.uk/member/genetic-disorders-uk/
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of December 31, 2021, QIAGEN employed more than 6,000 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).